西藏藥業(600211.SH):新活素繼續納入國家醫保藥品目錄
格隆匯11月28日丨西藏藥業(600211.SH)公佈,2019年11月28日,國家醫保局、人力資源社會保障部發布了新一輪的醫保價格談判結果,公司下屬全資子公司成都諾迪康生物製藥有限公司生產的注射用重組人腦利鈉肽(商品名:新活素)續約談判成功,被納入《國家基本醫療保險、工傷保險和生育保險藥品目錄》(2019年版)乙類範圍。
新活素醫保支付標準:445元(0.5mg/瓶),限二級及以上醫療機構用於規範治療效果不佳的急性失代償性心力衰竭短期治療,單次住院支付不超過3天。協議有效期:2020年1月1日至2021年12月31日,有效期滿後按照醫保有關規定調整支付標準。
新活素於2017年被納入《國家基本醫療保險、工傷保險和生育保險藥品目錄》(2017年版)乙類範圍,醫保支付標準:585元(0.5mg/瓶),本次降幅約24%。
新活素為公司的主要產品之一,2018年生產量144.50萬支,銷售量118.31萬支,銷售收入5.55億元,佔公司主營業務收入的54%;2019年上半年生產量65.3萬支,銷售量89.64萬支,銷售收入4.31億元,佔公司主營業務收入的70%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.